TB
MCID: MYC084
MIFTS: 68

Mycobacterium Tuberculosis 1 (TB)

Categories: Cardiovascular diseases, Endocrine diseases, Infectious diseases, Neuronal diseases, Rare diseases, Reproductive diseases, Respiratory diseases

Aliases & Classifications for Mycobacterium Tuberculosis 1

MalaCards integrated aliases for Mycobacterium Tuberculosis 1:

Name: Mycobacterium Tuberculosis 1 56
Tuberculosis 56 12 74 58 54 42 3 15 71 32
Tuberculosis, Susceptibility to 56 13 6
Tuberculoma 43 71
Mycobacterium Tuberculosis, Susceptibility to, 1 56
Mtbs1 56
Tb 47

Classifications:

Orphanet: 58  
Rare infertility disorders
Rare respiratory diseases
Rare endocrine diseases
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:399
OMIM 56 607949
MeSH 43 D014375
SNOMED-CT 67 15202009
ICD10 32 A15-A19
MESH via Orphanet 44 D014376
UMLS via Orphanet 72 C0041296
Orphanet 58 ORPHA3389
UMLS 71 C0041295 C0041296

Summaries for Mycobacterium Tuberculosis 1

MedlinePlus : 42 Tuberculosis (TB) is a disease caused by bacteria called Mycobacterium tuberculosis. The bacteria usually attack the lungs, but they can also damage other parts of the body. TB spreads through the air when a person with TB of the lungs or throat coughs, sneezes, or talks. If you have been exposed, you should go to your doctor for tests. You are more likely to get TB if you have a weak immune system. Symptoms of TB in the lungs may include A bad cough that lasts 3 weeks or longer Weight loss Loss of appetite Coughing up blood or mucus Weakness or fatigue Fever Night sweats Skin tests, blood tests, x-rays, and other tests can tell if you have TB. If not treated properly, TB can be deadly. You can usually cure active TB by taking several medicines for a long period of time.

MalaCards based summary : Mycobacterium Tuberculosis 1, also known as tuberculosis, is related to miliary tuberculosis and pulmonary tuberculosis, and has symptoms including fever, pruritus and snoring. An important gene associated with Mycobacterium Tuberculosis 1 is CD244 (CD244 Molecule), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Calcium carbonate and Bleomycin have been mentioned in the context of this disorder. Affiliated tissues include lungs, lymph nodes and pericardium, and related phenotypes are fatigue and fever

Disease Ontology : 12 A primary bacterial infectious disease that is located in lungs, located in lymph nodes, located in pericardium, located in brain, located in pleura or located in gastrointestinal tract, has material basis in Mycobacterium tuberculosis, which is transmitted by droplets released into the air when an infected person coughs or sneezes.

CDC : 3 Tuberculosis (TB) is caused by a bacterium called Mycobacterium tuberculosis. The bacteria usually attack the lungs, but TB bacteria can attack any part of the body such as the kidney, spine, and brain. Not everyone infected with TB bacteria becomes sick. As a result, two TB-related conditions exist: latent TB infection (LTBI) and TB disease. If not treated properly, TB disease can be fatal.

Wikipedia : 74 Tuberculosis (TB) is an infectious disease usually caused by Mycobacterium tuberculosis (MTB) bacteria.... more...

More information from OMIM: 607949

Related Diseases for Mycobacterium Tuberculosis 1

Diseases in the Mycobacterium Tuberculosis 1 family:

Mycobacterium Tuberculosis 2 Mycobacterium Tuberculosis 3

Diseases related to Mycobacterium Tuberculosis 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2152)
# Related Disease Score Top Affiliating Genes
1 miliary tuberculosis 35.6 TNF IFNGR1 IFNG ADA
2 pulmonary tuberculosis 35.5 TNF TLR2 SLC11A1 INHA IL4 IL10
3 gastrointestinal tuberculosis 35.3 TNF IFNG ADA
4 pleural tuberculosis 35.3 TNF IFNG ADA
5 extrapulmonary tuberculosis 35.2 TNF TLR2 SLC11A1 IL10 IFNGR1 IFNG
6 central nervous system tuberculosis 35.1 TNF IFNG ADA
7 oral tuberculosis 35.1 TNF IFNG GNLY
8 abdominal tuberculosis 35.0 TNF IFNG ADA
9 pericardial tuberculosis 34.8 IFNG ADA
10 tuberculous meningitis 34.4 TNF TLR2 ADA
11 tuberculous peritonitis 33.6 IFNG ADA
12 lung disease 33.5 TNF TLR2 SLC11A1 IL4 IL17A IL10
13 silicosis 33.5 TNF IL4 IL17A IL10
14 human immunodeficiency virus type 1 33.4 TNF IL10 IFNG CD209 ADA
15 aspergillosis 33.4 TNF TLR2 IL4 IL10 IFNG CD209
16 nontuberculous mycobacterial lung disease 33.3 TNF TLR2 SLC11A1
17 melioidosis 33.3 TNF TLR2 IL10 IFNG
18 buruli ulcer 33.3 SLC11A1 IL10 IFNG
19 orofacial granulomatosis 33.3 TNF IL4 IL10 IFNG
20 mycobacterium fortuitum 33.3 IFNGR1 HSPD1
21 pleural disease 33.2 TNF IFNG ADA
22 mycobacterium abscessus 32.7 TNF TLR2
23 lymphadenitis 32.5 TNF SLC11A1 IL10 IFNGR1 IFNG CD209
24 immune deficiency disease 32.4 TNF TLR2 IL4 IL10 IFNGR1 IFNG
25 sarcoidosis 1 32.4 TNF SLC11A1 IFNG ADA
26 meningitis 32.4 TNF TLR2 IL4 IL17A IL10 IFNG
27 leprosy 3 32.3 TNF TLR2 SLC11A1 IL4 IL17A IL10
28 acquired immunodeficiency syndrome 32.3 TNF IL10 IFNG ADA
29 pleurisy 32.3 TNF TLR2 IFNG ADA
30 crohn's disease 32.3 TNF TLR2 SLC11A1 IL4 IL17A IL10
31 diabetes mellitus 32.2 TNF TLR2 IL4 IL17A IL10 IFNG
32 spondylitis 32.2 TNF IL17A IL10 IFNG
33 peritonitis 32.2 TNF TLR2 IL4 IL17A IL10 IFNG
34 osteomyelitis 32.2 TNF TLR2 IL4 IL10 IFNGR1 IFNG
35 uveitis 32.1 TNF IL4 IL17A IL10 IFNG HSPD1
36 allergic hypersensitivity disease 32.1 TNF IL4 IL17A IL10 IFNG
37 pneumonia 32.1 TNF TLR2 IL4 IL17A IL10 IFNG
38 bacterial infectious disease 32.0 TNF TLR2 SLC11A1 IL17A IL10 IFNG
39 bronchitis 32.0 TNF TLR2 IL4 IL10
40 vasculitis 32.0 TNF IL17A IL10 HSPD1
41 syphilis 32.0 TNF IL17A IFNG CD209
42 pneumoconiosis 32.0 TNF IL4 IL17A IL10
43 brucellosis 31.9 TNF SLC11A1 IL4 IL17A IL10 IFNG
44 lymphopenia 31.9 IL4 IL10 IFNG ADA
45 pericarditis 31.9 TNF IFNG ADA
46 autoimmune disease 31.9 TNF SLC11A1 IL4 IL17A IL10 IFNG
47 human immunodeficiency virus infectious disease 31.9 TNF IL4 IL10 IFNG CD209 ADA
48 inflammatory bowel disease 31.8 TNF TLR2 SLC11A1 IL4 IL17A IL10
49 plague 31.8 TNF TLR2 IL10
50 purpura 31.8 TNF IL4 IL10 IFNG

Graphical network of the top 20 diseases related to Mycobacterium Tuberculosis 1:



Diseases related to Mycobacterium Tuberculosis 1

Symptoms & Phenotypes for Mycobacterium Tuberculosis 1

Human phenotypes related to Mycobacterium Tuberculosis 1:

58 31
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fatigue 58 31 frequent (33%) Frequent (79-30%) HP:0012378
2 fever 58 31 frequent (33%) Frequent (79-30%) HP:0001945
3 weight loss 58 31 frequent (33%) Frequent (79-30%) HP:0001824
4 cough 58 31 frequent (33%) Frequent (79-30%) HP:0012735
5 abnormal lung morphology 58 31 frequent (33%) Frequent (79-30%) HP:0002088

Clinical features from OMIM:

607949

UMLS symptoms related to Mycobacterium Tuberculosis 1:


fever, pruritus, snoring, coughing

MGI Mouse Phenotypes related to Mycobacterium Tuberculosis 1:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.13 ADA CD244 CISH HSPD1 IFNG IFNGR1
2 digestive/alimentary MP:0005381 10.1 ADA IFNG IFNGR1 IL10 IL17A IL4
3 endocrine/exocrine gland MP:0005379 10.07 ADA CISH IFNG IFNGR1 IL10 IL17A
4 immune system MP:0005387 10.03 ADA CD244 CISH IFNG IFNGR1 IL10
5 liver/biliary system MP:0005370 9.76 ADA IFNG IFNGR1 IL10 IL4 INHA
6 neoplasm MP:0002006 9.5 IFNG IFNGR1 IL10 INHA SLC11A1 TLR2
7 respiratory system MP:0005388 9.28 ADA CISH HSPD1 IFNG IL10 IL17A

Drugs & Therapeutics for Mycobacterium Tuberculosis 1

Drugs for Mycobacterium Tuberculosis 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 514)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Calcium carbonate Approved, Investigational Phase 4 471-34-1
2
Bleomycin Approved, Investigational Phase 4 11056-06-7 5360373
3
Lumefantrine Approved Phase 4 82186-77-4 6437380
4
Artemether Approved Phase 4 71963-77-4 68911 9796294 119380
5
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
6
Abacavir Approved, Investigational Phase 4 136470-78-5 441300 65140
7
Dapsone Approved, Investigational Phase 4 80-08-0 2955
8
Sulfamethoxazole Approved Phase 4 723-46-6 5329
9
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
10
Nelfinavir Approved Phase 4 159989-64-7 64143
11
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
12
Ustekinumab Approved, Investigational Phase 4 815610-63-0
13
Tranexamic Acid Approved Phase 4 1197-18-8 5526
14 Brodalumab Approved, Investigational Phase 4 1174395-19-7
15
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
16
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
17
Halofantrine Approved Phase 4 69756-53-2 37393
18
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
19
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
20
Spironolactone Approved Phase 4 52-01-7, 1952-01-7 5833
21
Bisoprolol Approved Phase 4 66722-44-9 2405
22
Budesonide Approved Phase 4 51333-22-3 63006 5281004
23
Clobetasol Approved, Experimental, Investigational Phase 4 25122-41-2, 25122-46-7 32798 5311051
24
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
25
Methadone Approved Phase 4 76-99-3 4095
26
Streptomycin Approved, Vet_approved Phase 4 57-92-1 19649
27
Gatifloxacin Approved, Investigational Phase 4 112811-59-3 5379
28
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
29
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
30
Meropenem Approved, Investigational Phase 4 96036-03-2, 119478-56-7 441130 64778
31
Cilastatin Approved, Investigational Phase 4 82009-34-5 5280454 6435415
32
Imipenem Approved Phase 4 74431-23-5, 64221-86-9 104838
33
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
34
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
35
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
36
Mycophenolic acid Approved Phase 4 24280-93-1 446541
37
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
38
Abatacept Approved Phase 4 332348-12-6 10237
39
Bedaquiline Approved Phase 4 843663-66-1
40
Linezolid Approved, Investigational Phase 4 165800-03-3 441401
41
Ethambutol Approved Phase 4 74-55-5 3279 14052
42
Pyrazinamide Approved, Investigational Phase 4 98-96-4 1046
43
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
44
Ofloxacin Approved Phase 4 82419-36-1 4583
45
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
46
Zidovudine Approved Phase 4 30516-87-1 35370
47
Cycloserine Approved Phase 4 68-41-7 401 6234
48
Aminosalicylic Acid Approved Phase 4 65-49-6 4649
49
Prothionamide Approved, Investigational Phase 4 14222-60-7 666418
50
Ethinyl Estradiol Approved Phase 4 57-63-6 5991

Interventional clinical trials:

(show top 50) (show all 1528)
# Name Status NCT ID Phase Drugs
1 The Study of Standardized Preoperative Anti-tuberculosis Treatment of Surgical Treatment of Spinal Tuberculosis Patients Unknown status NCT02477852 Phase 4 Isoniazid;Rifampicin;Ethambutol;Pyrazinamide
2 The Relationships Between Gene Polymorphisms of LTA4H and Dexamethasone Treatment for Tuberculous Meningitis Unknown status NCT02588196 Phase 4 Dexamethasone acetate
3 The Impact of the Simple Verbal Intervention for Adequately Collecting Sputum and the Acceptable Specimen Based on Gram Stain, on the Results of Sputum Acid-fast Bacilli Smear Testing Unknown status NCT01135043 Phase 4
4 The Application of the N-acetyltransferase 2 (NAT2) Genotyping in Re-challenge Protocol of Isoniazid (INH) Titration in Patients With Anti-TB Medications-induced Hepatitis Unknown status NCT00728546 Phase 4 Isoniazid (Rifinah)
5 Effect of Vitamin D as Adjunctive Therapy in Patients With Pulmonary Evolution Tuberculosis in the National Institute of Respiratory Diseases Unknown status NCT02464683 Phase 4
6 Randomized, Controlled Trial Comparing Efficacy of Percutaneous and Intradermal Vaccination With Japanese (Tokyo) 172 BCG in the Prevention of Tuberculosis In Infants Vaccinated at Birth Unknown status NCT00242047 Phase 4
7 International Multicenter Trial for the Evaluation of a Four-Drug Fixed Dose Combined Tablet Daily in the Initial Intensive Phase of Chemotherapy Followed by a Two-Drug Fixed Dose Combined Tablet Three Times a Week in the Continuation Phase for the Treatment of Pulmonary Tuberculosis Unknown status NCT00216333 Phase 4 combined fixed dose combination
8 Evaluation of the Pharmacokinetics of Antituberculosis Drugs and Tuberculosis Treatment Outcomes in HIV-tuberculosis Co-infected Ugandan Adults Unknown status NCT01782950 Phase 4 Rifampicin, Isoniazid, Ethambutol, Pyrazinamide
9 Different Reintroduction Regimens of Antituberculosis Drugs After Development of Hepatitis During Anti-tuberculosis Treatment Unknown status NCT01395654 Phase 4 isoniazid, rifampin, pyrazinamide
10 Integral Research of the Managing and Treatment of the Infection With Human Immunodeficiency (VIH) /Human Immunodeficiency Syndrome(SIDA) Co-infection With Latent Tuberculosis Infection. A Multidisciplinary and Interinstitucional Approach Unknown status NCT01875952 Phase 4 Isoniazid
11 New Super-short Course Regimen for Retreatment Pulmonary Tuberculosis Unknown status NCT02331823 Phase 4 Isoniazid Aminosalicylate Tablets;Streptomycin injectable
12 Shortened Regimens for First Diagnosed Smear Positive Drug Susceptible Pulmonary Tuberculosis: a Randomised Controlled Non-inferiority Trial Unknown status NCT02901288 Phase 4 Isoniazid;Rifampicin;Pyrazinamide;Ethambutol;Levofloxacin
13 Phase IV Study of the Quantiferon-RD1 Test Unknown status NCT00311220 Phase 4 tuberculin for skin test
14 Efficacy and Safety of an Initial Regimen Raltegravir (RAL) + Lamivudine/Abacavir Fixed-Dose Combination (3TC/ABC FDC) for 48 Weeks in ART-naïve, HIV/TB Co-Infected Adult Subjects Receiving Rifabutin-containing, 1-line Anti-TB Therapy Unknown status NCT01059422 Phase 4 Raltegravir; Abacavir/Lamivudine
15 Prophylactic Use of Entecavir to Reduce Hepatitis Flare in Highly Viremic HBV Patients With Active Tuberculosis Receiving Anti-tuberculous Treatment Unknown status NCT01724723 Phase 4 entecavir (BARACLUDE®)
16 Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Comparison With Tuberculin Skin Test in Patients With Psoriasis and Psoriatic Arthritis Unknown status NCT01223976 Phase 4
17 the Safety and Effect in TB Patients With NAC Unknown status NCT02889757 Phase 4 Acteylcysteine
18 Risk of Tuberculosis and Infections in Spondyloarthritis Patients Treated With Tofacitinib in Bangladesh Unknown status NCT03504072 Phase 4 Tofacitinib 5 mg,;Etanercept
19 Testing if BCG (Bacille Calmette-Guérin) Vaccination Can Induce Innate Immune Training in Adult People Above 50 Years of Age in Guinea-Bissau Unknown status NCT02953327 Phase 4
20 Systematic Empirical vs. Test-guided Anti-tuberculosis Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating Antiretroviral Therapy With CD4 Cell Counts <100/mm3: the STATIS Randomized Controlled Trial Unknown status NCT02057796 Phase 4 ART (Atripla, Truvada, Efavirenz, Combivir);Rifampin, isoniazid, pyrazinamide, ethambutol
21 Comparing Treatment Efficacy With High and Medium Dose of Fluticasone in Combination With Salmeterol in COPD Patients Unknown status NCT01657487 Phase 4 Fluticasone/Salmeterol high dose
22 Effect of Supplementary Vitamin D in Patients With Diabetes Mellitus and Pulmonary Tuberculosis (EVIDENT Study): a Randomized, Double Blind, Controlled Trial Unknown status NCT02169570 Phase 4
23 The Efficacy of Intra-lesional Bleomycin Versus Intra-lesional Purified Protein Derivative in Treatment of Palmoplantar Warts Unknown status NCT03477448 Phase 4 Bleomycin;Purified Protein Derivative
24 The Influence of BCG Vaccine as a Booster TDaP-IPV Vaccination: an Explorative Study Unknown status NCT02771782 Phase 4
25 Pharmacokinetic Interaction Between Coartem® and Either Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients Unknown status NCT00620438 Phase 4 Lumefantrine-artemether and nevirapine;lumefantrine-artemether and efavirenz;Lumefantrine-artemether and rifampicin
26 The Effect of Maternal Antenatal Steroid Administration on the Blood Flow Through the Pulmonary Artery in the Term Fetus; a Randomized Control Double Blinded Study Unknown status NCT02978976 Phase 4 Betamethasone;saline
27 D-cycloserine for Relapse Prevention Following Intravenous Ketamine in Treatment-resistant Depression Unknown status NCT02772211 Phase 4 Ketamine;D-cycloserine;Placebo
28 PET/CT and Roentgen in Lung Cancer. Evaluation of Patients in General Practice Unknown status NCT00675168 Phase 4
29 Randomized Trial for Pharmacogenomics-based Tuberculosis Therapy (RT-PGTT) Completed NCT00298870 Phase 4 Isoniazid;isoniazed
30 Multicenter Open Non-Comparative Clinical Study to Evaluate the Efficacy and Safety of Three Months TAVANIC Course (Levofloxacin) in Combine Treatment of Multi-Drug-Resistant Tuberculosis (MDR-TB) Completed NCT00495339 Phase 4 Levofloxacin
31 Cost-effectiveness of Quantiferon Gold in VITRO Test of T-lymphocytic Response for Detection of Latent Tuberculosis in At-risk Healthcare Workers Completed NCT00797836 Phase 4
32 A Pilot Study Of Open-Label Fixed Dose Combination Zidovudine/Lamivudine/Abacavir In HIV-Infected Persons With Tuberculosis In Moshi, Tanzania; Tuberculosis And HIV Immune Reconstitution Syndrome Trial (THIRST) Completed NCT00851630 Phase 4 Fixed dose combination zidovudine/lamivudine/abacavir
33 Comparison of Two Strategies for Therapeutic Decision-making in Tuberculosis Contact Tracing: a Standard Strategy Based on Tuberculin Skin Test (TST) Alone vs TST Combined With QuantiFERON®-TB Gold In-Tube (QFT-IT) Completed NCT01223534 Phase 4 Preventive treatment with Isoniazid.;Preventive treatment with Isoniazid
34 Population Pharmacokinetic Analysis of Dapsone in Normal, Overweight and Obese Volunteers Completed NCT01165840 Phase 4 Dapsone
35 A Randomized, Placebo-Controlled Study of Limited vs. Continuous Isoniazid Tuberculosis Preventive Therapy in HIV-infected Persons in Botswana Completed NCT00164281 Phase 4 Isoniazid
36 The Pharmacokinetic Effect of Clarithromycin on the AUC0-12h of Linezolid in Multidrug-resistant and Extensively Drug-resistant Tuberculosis (MDR/XDR-TB) Patients Completed NCT01521364 Phase 4 Addition of different doses of clarithromycin.
37 Comparison of Quantiferon-TB Gold Assay With Tuberculin Skin Testing for Detecting Latent Mycobacterium Tuberculosis Infection in Patients With Chronic Liver Disease Awaiting Liver Transplantation Completed NCT00402402 Phase 4
38 TBTC Study 23B:Intensive Pharmacokinetics of the Nelfinavir Rifabutin Interaction in Patients With HIV-Related Tuberculosis Treated With a Rifabutin-Based Regimen Completed NCT00023400 Phase 4 Nelfinavir;Rifabutin
39 Evaluation of Three Regimens of Chemoprophylaxis for Tuberculosis in Patients co-Infected by HIV and Mycobacterium Tuberculosis Completed NCT00402454 Phase 4 isoniazid, rifampin + isoniazid or rifampin + pyrazinamide
40 Evaluation of 2 Interferon γ Assays (QuantiFERON TB Gold In-Tube® and T-SPOT.TB®) in the Diagnosis of Latent Tuberculosis in HIV-infected Patients.ANRS EP 40 QUANTI SPOT Completed NCT00647205 Phase 4
41 Effect of HIV and/or Active Tuberculosis on the Humoral and Cell Mediated Immune Responses to Un-adjuvanted Trivalent Sub-unit Influenza Vaccine (TIV) in Adults Completed NCT01811823 Phase 4
42 Drugs for Treatment of Latent Tuberculosis Infection Objective 4: Identify Biomarkers for Clinical Trials of Drugs Active Against Latent TB Completed NCT00293228 Phase 4 Isoniazid;isoniazid
43 Rapid Detection of Rifampin and Isoniazid Resistance by PCR Before Tuberculosis (TB) Treatment Initiation: a National Multicenter Randomized Clinical Trial Completed NCT02231229 Phase 4 conventional therapy
44 Optimal Dosing of 1st Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study) Completed NCT01637558 Phase 4 8 hourly LPV/r during TB treatment;Nevirapine;Lopinavir/Ritonavir
45 Pilot Roll Out of the Xpert MTB/Rif for the Diagnosis of Pulmonary Tuberculosis in Two Municipalities in Brazil: a Stepped Wedge Trial Completed NCT01363765 Phase 4
46 Study of Safety and Efficacy of Different Regimes of Reintroduction of Anti-TB Drugs in Antituberculosis Treatment Induced Hepatotoxicity Completed NCT00405301 Phase 4 Rifampicin(max dose 10 mg/kg/day), Isoniazide (max dose 5 mg/kg/day) and Pyrazinamide (max dose 25 mg/kg/day)
47 An Evaluation of the Pharmacological Interaction of Lopinavir 800mg - Ritonavir 200mg Combination and Rifampin in Subjects Presenting Tuberculosis, With Contraindication for Antiretroviral Regimens Including Efavirenz Completed NCT00771498 Phase 4 Lopinavir
48 A Pharmacokinetics Study Comparing Lopinavir Plasma Exposure When Given as Lopinavir/Ritonavir (1:1) in the Presence of Rifampicin and Lopinavir/Ritonavir (4:1) Without Rifampicin in HIV and TB Co-infected Children in South Africa. Completed NCT02348177 Phase 4 lopinavir with ritonavir in 1:1 ratio;Lopinavir/ritonavir 4:1
49 A Randomized Trial of Three Regimens to Prevent Tuberculosis in HIV-Infected Patients With Anergy Completed NCT00402610 Phase 4 isoniazid, rifampin + isoniazid, rifampin + pyrazinamide or not treatment
50 Impact of TB Preventive Therapy for HIV/TB Co-infected Patients With Access to Highly Active Antiretroviral Therapy in Rio de Janeiro, Brazil: A Phased Implementation Trial Completed NCT00107887 Phase 4 INH preventive therapy;TST (tuberculin skin test)

Search NIH Clinical Center for Mycobacterium Tuberculosis 1

Inferred drug relations via UMLS 71 / NDF-RT 50 :


aminosalicylic acid
Antitubercular Agents
Ethambutol
Ethambutol Hydrochloride
Ethionamide
isoniazid
Pyrazinamide

Cochrane evidence based reviews: tuberculoma

Genetic Tests for Mycobacterium Tuberculosis 1

Anatomical Context for Mycobacterium Tuberculosis 1

The Foundational Model of Anatomy Ontology organs/tissues related to Mycobacterium Tuberculosis 1:

19
Lungs, Lymph Nodes, Pericardium, Brain, Pleura, Gastrointestinal Tract

MalaCards organs/tissues related to Mycobacterium Tuberculosis 1:

40
Testes, Lung, Skin, Bone, Breast, Kidney, Lymph Node

Publications for Mycobacterium Tuberculosis 1

Articles related to Mycobacterium Tuberculosis 1:

(show top 50) (show all 31218)
# Title Authors PMID Year
1
Linkage of tuberculosis to chromosome 2q35 loci, including NRAMP1, in a large aboriginal Canadian family. 56 54
10882571 2000
2
Epidemiology of Tuberculosis in the United States. 42 61
31731978 2019
3
CISH and susceptibility to infectious diseases. 6
20484391 2010
4
Noncountable Tuberculosis Case Reporting, National Tuberculosis Surveillance System, United States, 2010-2014. 42
31722186 2020
5
Geriatric TB: Needs focussed attention under RNTCP. 42
31813443 2019
6
TNF in host resistance to tuberculosis infection. 61 54
20173394 2010
7
The Mycobacterium tuberculosis cytochrome P450 system. 61 54
19635450 2010
8
cAMP signaling in Mycobacterium tuberculosis. 61 54
19634702 2009
9
Structure-activity relationships of compounds targeting mycobacterium tuberculosis 1-deoxy-D-xylulose 5-phosphate synthase. 54 61
18783951 2008
10
Interferon gamma assays for tuberculosis in children. 61 54
18846802 2008
11
IL-23 and IL-17 in tuberculosis. 54 61
18218322 2008
12
CD209 genetic polymorphism and tuberculosis disease. 61 54
18167547 2008
13
Host innate immune response to Mycobacterium tuberculosis. 61 54
17364232 2007
14
Tumor necrosis factor and tuberculosis. 54 61
17502865 2007
15
Th2 cytokines in susceptibility to tuberculosis. 61 54
17504117 2007
16
Mycobacterium tuberculosis complex in atherosclerosis. 54 61
16418767 2005
17
The unusual chaperonins of Mycobacterium tuberculosis. 54 61
16253564 2005
18
Protective responses in tuberculosis: induction of genes for interferon-gamma and cytotoxicity by Mycobacterium tuberculosis and during human tuberculosis. 61 54
15320888 2004
19
Metabolism of 2-methyladenosine in Mycobacterium tuberculosis. 61 54
15207808 2004
20
[Tuberculosis in compromised hosts]. 61 54
14672050 2003
21
Mannose-binding lectin polymorphisms in clinical tuberculosis. 54 61
12934195 2003
22
[Serum adenosine deaminase activity in pulmonary tuberculosis]. 61 54
15143406 2003
23
[Up-to-date understanding of tuberculosis immunity]. 61 54
12683337 2003
24
Genetic basis of tuberculosis susceptibility in India. 54 61
12501922 2002
25
P2X7 receptors and apoptosis in tuberculosis infection. 61 54
11693438 2001
26
Advances in the immunopathogenesis of pulmonary tuberculosis. 54 61
11371766 2001
27
Production of interleukin-18 in human tuberculosis. 61 54
10882602 2000
28
Human genetic susceptibility to tuberculosis. 54 61
10976382 2000
29
The NRAMP1 gene and susceptibility to tuberculosis. 54 61
9669915 1998
30
The NRAMP1 gene and susceptibility to tuberculosis. 61 54
9669916 1998
31
Host genetic susceptibility to human tuberculosis. 54 61
9949798 1998
32
[Construction of mycobacterium tuberculosis genomic library]. 54 61
10072801 1997
33
Alcohol, tumor necrosis factor, and tuberculosis. 61 54
7771645 1995
34
Mycobacterium tuberculosis expresses two chaperonin-60 homologs. 61 54
7681982 1993
35
Soluble interleukin-2 receptors in pulmonary tuberculosis. 61 54
2101408 1990
36
Drug-resistant tuberculosis: an experience from Qatar. 61
32238120 2020
37
Endobronchial tuberculosis polyps. 61
32528684 2020
38
Long non-coding RNA molecules in tuberculosis. 61
32283111 2020
39
Tuberculosis in Pregnancy. 61
32459437 2020
40
Tuberculosis in term pregnancy. 61
31706736 2020
41
Tuberculosis Healthcare Workers: There Goes My Hero. 61
32502233 2020
42
Bovine Tuberculosis: A Re-emerging Zoonotic Infection. 61
32478614 2020
43
Think tuberculosis-but is thinking enough? 61
32178763 2020
44
[Tuberculosis infection in an unusual location]. 61
32274907 2020
45
Tuberculosis in children: screening, diagnosis and management. 61
32374579 2020
46
Isolated hepatic tuberculosis presenting as hydatid cyst. 61
31758483 2020
47
Nomogram to predict multidrug-resistant tuberculosis. 61
32505203 2020
48
Development and Challenges in Animal Tuberculosis Vaccination. 61
32549360 2020
49
Cavitary tuberculosis: the gateway of disease transmission. 61
32482293 2020
50
The monogenic basis of human tuberculosis. 61
32055999 2020